Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.65 |
| ▸ | TNKS | O95271 | 3/20 | 0.64 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24624758 | 0.90 | PARP1 (0.71) | PARP1TNKSTNKS2 | |
| SCHEMBL29923122 | 0.90 | PARP1 (0.71) | PARP1TNKSTNKS2 | |
| SCHEMBL29922956 | 0.90 | PARP1 (0.71) | PARP1TNKSTNKS2 | |
| SCHEMBL28975588 | 0.85 | PARP1 (0.81) | PARP1TNKSTNKS2 | |
| SCHEMBL29922994 | 0.84 | PARP1 (0.76) | PARP1TNKSTNKS2 | |
| SCHEMBL29923010 | 0.84 | PARP1 (0.76) | PARP1TNKSTNKS2 | |
| SCHEMBL23113221 | 0.84 | PARP1 (0.75) | PARP1TNKSTNKS2 | |
| SCHEMBL22656867 | 0.83 | PARP1 (0.75) | PARP1TNKSTNKS2 | |
| SCHEMBL29535734 | 0.83 | PARP1 (0.75) | PARP1TNKSTNKS2 | |
| SCHEMBL29722673 | 0.83 | PARP1 (0.77) | PARP1TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-04-20 | — | — | US | disclosed |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-04-20 | — | — | US | disclosed |
| EP-3793608-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | PARP1 1873/4885TNKS 2187/4885TNKS2 2124/4885 |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | PARP1 1873/4885TNKS 2187/4885TNKS2 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.